Pancreatic Cancer Clinical Trial

A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant
Therapy for
Resectable and Borderline Resectable Adenocarcinoma
of the Pancreatic Head, Neck or Uncinate Process

 

Personalized Medicine Clinical Trial for Pancreatic Cancer

Background: This trial takes a novel, personalized, neoadjuvant approach to treatment of pancreatic cancer. Six specific molecular targets have been identified that are predictive of chemosensitivity to agents commonly used to treat pancreatic cancer today. Investigators will analyze the individual patient's tumor for these molecular target(s) and individualize the neoadjuvant treatment based on the immunohistochemistry and quantitative reverse transcriptase PCR data.

Eligibility/Treatment Schema: Eligible patients include those with known or suspected resectable or borderline resectable adenocarcinoma of the pancreas. Patients will undergo endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) of their tumors and those samples which are positive for adenocarcinoma will undergo molecular profiling. The patient will then undergo neoadjuvant therapy based on their tumor's molecular profile. If no profile is discernible, the patient will receive neoadjuvant therapy based on current standard of care. Those patients who demonstrate stable disease or treatment response by biochemical, clinical and radiologic measures will be offered resection. The primary objective is to compare resectability rate with targeted neoadjuvant therapy to historical results utilizing neoadjuvant therapy that is non-targeted. Please refer to the treatment schemas: Resectable (Figure A) and Borderline Resectable (Figure B); and the molecular profiling algorithms: FNA profiling (Figure C), Resection Profiling, no previous XRT (Figure D), and Resection Profiling, previous XRT (Figure E).

Contacts/Referrals: If you have specific questions regarding this clinical trial, you may contact any of the following investigators listed below. If you wish to refer a patient for this study, you may contact any one of the individual investigators or schedule the patient through our journey coordinator, Gail Laschen.
 

Gail Laschen - Patient Scheduling/Intake
Office: 414-805-6849
Pager: 414-590-0718
Email: glaschen@froedterthealth.org

Ann Dwyer – Research Nurse Coordinator
Office: 414-805-8943
Pager: 414-318-4883
Email: adwyer@mcw.edu

Kathleen Christians, MD - Surgical Oncology
Office: 414-805-9720
Pager: 414-557-3979
Email: kchristi@mcw.edu
Fax:    414-805-5934

Douglas B. Evans, MD – Surgical Oncology
Office: 414-805-5706
Pager: 414-557-3104
Email: devans@mcw.edu
Fax:    414-259-9225

Paul Ritch, MD - Medical Oncology
Office: 414-805-4611
Pager: 414-557-8379
Email: pritch@mcw.edu
Fax:    414-805-4606

Ben George, MD – Medical Oncology
Office: 414-805-4686
Pager: 414-318-9330
Email: bgeorge@mcw.edu
Fax:    414-805-4606

Beth Erickson, MD - Radiation Oncology
Office: 414-805-4460
Pager: 414-557-9418
Email: berickson@mcw.edu
Fax:    414-805-4369

Tracy Kelly, MD – Radiation Oncology
Office: 414-805-4475
Pager: 414-557-7302
Email: tkelly@mcw.edu
Fax:    414-805-4369

Pancreatic Care Team
 

 

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2014

Page Updated 10/30/2014
Top